The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal, pulmonary and ophthalmic disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.本發明係有關一種包含(3S)-3-(4-氯-3-{[(2S,3R)-2-(4-氯苯基)-4,4,4-三氟-3-甲基丁醯基]胺基}苯基)-3-環丙基丙酸鈉之可口服的修飾釋放藥物劑型，及製備該劑型之方法，及其於治療及/或預防疾病，特別是治療及/或預防心臟、腎臟、肺臟與眼部疾患、中樞神經系統疾患、纖維化與發炎疾患、及代謝疾患上之用途。
